Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 47.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,767,982 shares of the company's stock after buying an additional 572,729 shares during the period. Y-mAbs Therapeutics accounts for about 3.7% of Caligan Partners LP's investment portfolio, making the stock its 9th largest position. Caligan Partners LP owned about 3.95% of Y-mAbs Therapeutics worth $13,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in Y-mAbs Therapeutics during the 4th quarter valued at approximately $46,000. Wells Fargo & Company MN grew its holdings in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after purchasing an additional 6,131 shares in the last quarter. SG Americas Securities LLC increased its position in Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares during the last quarter. XTX Topco Ltd raised its stake in Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock valued at $163,000 after purchasing an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock valued at $174,000 after purchasing an additional 1,903 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 22.50% of the stock is currently owned by corporate insiders.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $4.25 on Thursday. The firm has a market capitalization of $192.18 million, a price-to-earnings ratio of -7.87 and a beta of 0.71. The company has a 50-day moving average of $4.76 and a 200 day moving average of $7.98. Y-mAbs Therapeutics, Inc. has a 1-year low of $3.84 and a 1-year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same period last year, the company earned ($0.02) EPS. On average, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wedbush restated an "outperform" rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Truist Financial decreased their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Bank of America downgraded Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research report on Tuesday, April 22nd. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Finally, HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.40.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.